Pharmaceutical Industry Reports Drug Abuse Treatment Market | Page 2

REPORT DESCRIPTION
Drug Abuse Treatment Market – Overview
In 2017, Indivior PLC received the U.S. Food and Drug Administration (FDA) approval for SUBLOCADE
(buprenorphine extended- release) injection for subcutaneous use, which is indicated for treatment of moderate to
severe opioid use disorder. Furthermore, in 2016, Teva Pharmaceutical Industries Ltd. launched a generic version
of CAMPRAL1 (acamprosate calcium) delayed-release tablets, 333 mg in the U.S. market, which is indicated for
the treatment and maintenance of abstinence from alcohol in patients with alcohol dependence. Moreover, in April
2018, Dr. Reddy's Laboratories received the U.S. Food and Drug Administration (FDA) approval to launch
generic version of Suboxone sublingual film for all dosage forms 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12
mg/3 mg indicated for the treatment of drug addiction. Suboxone is a combination of Buprenorphine and
Naloxone.
In 2014, British American Tobacco plc. received approval from the UK Medicines and Healthcare products
regulatory agency for new products nicotine inhaler. This new inhaler will help to quit smoking habits of addicted
smokers, this new inhaler contains the same propellant found in an asthma inhaler and gives an immediate hit of
nicotine through a breath-operated valve. In 2015 company launched nicotine inhaler in the UK. Frequent
launches of such novel drugs in market are expected to fuel the global drug abuse treatment market growth.